A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Ideaya Biosciences

Status and phase: Enrolling; Phase 1

Conditions: Breast Cancer; Pancreas Cancer; Ovarian Cancer; Advanced or Metastatic Solid Tumors; Prostate Cancer

Treatments: Drug: IDE-161

Study type: Interventional

Funder types: Industry

Identifiers

NCT05787587

IDE161-001

Details and patient eligibility

About

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161.

Full description

The purpose of this study is to characterize the safety, tolerability including determination of maximum tolerated dose (MTD), maximum accepted dose (MAD), recommended dose(s) for expansion (RDE) and/or recommended Phase 2 dose (RP2D), pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of IDE161 as a single agent in participants with advanced or metastatic solid tumors harboring BRCA1/2 loss of function alterations and/or other defects in the homologous recombination (HR) pathway.

Enrollment: 68 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Adult participants must be 18 years of age or older
2. Advanced or metastatic solid tumors excluding primary central nervous system (CNS) tumors
3. Have documented evidence of genetic alterations conferring homologous recombination deficiency
4. Participant must have progressed on at least one prior line of therapy in the advanced or metastatic setting that is considered an appropriate standard of care, or for which the participant has documented intolerance

Exclusion criteria

1. Known primary CNS malignancy
2. Impairment of GI function or GI disease that may significantly alter the absorption of IDE161
3. Have active, uncontrolled infection
4. Clinically significant cardiac abnormalities
5. Major surgery within 4 weeks prior to enrollment
6. Radiation therapy within 2 weeks prior to enrollment
7. Systemic cytotoxic chemotherapy within 4 weeks prior to enrollment
8. Radioimmunotherapy within 6 weeks of enrollment
9. Treatment with a therapeutic antibody within 4 weeks prior to enrollment
10. Treatment with an anti-cancer small molecule within 5 half-lives (t1/2), or 2 weeks, whichever is shorter

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

68 participants in 2 patient groups

Module 1 Part 1: Monotherapy Dose Escalation

Experimental group

Description:

Participants will be assigned to a dose level.

Treatment:

Drug: IDE-161

Module 1 Part 2: Monotherapy Dose Expansion

Experimental group

Description:

After a dose is decided in Part 1, participants entering part 2 will be assigned to a dose level.

Treatment:

Drug: IDE-161